You have done the reading. You know the early hormone-scare headlines were followed by years of reanalysis, and you want current, balanced guidance rather than a shrug and a suggestion to wait it out. One question comes up again and again once hormone support is on the table: does the format (an injection, a cream, or a pellet) actually matter, and how does a clinician think it through?
This article is educational and is not medical advice. The right approach for any individual is a decision made with an independent, licensed provider who knows your history, your labs, and your goals. What follows is how thoughtful clinicians frame the trade-offs, so you can walk into that conversation informed.
Why format is a real clinical question, not a marketing choice
Hormones behave differently depending on how they enter the body. A key example: how estrogen is delivered appears to change its effect on the blood clotting and cardiovascular system. Major medical society guidance notes that transdermal estrogen (patch, gel, or cream) is generally associated with a lower risk of venous blood clots than oral estrogen, because it does not pass through the liver first in the same concentrated way [1][2]. That single mechanistic difference ("first-pass" liver metabolism) is why route of delivery is a genuine safety conversation, not a preference poll.
The North American Menopause Society (now The Menopause Society) 2022 position statement reaffirmed that hormone therapy remains an appropriate option for many women, and that the balance of benefit and risk depends heavily on a woman's age, time since menopause, and individual risk profile [1]. For a woman who began menopause years ago, and for a woman who entered menopause early through surgery, those profiles look very different, which is exactly why a real plan is individualized.
The "timing" question, addressed directly
If you started menopause a few years back and wonder whether it is "too late," the concept clinicians use is the timing hypothesis: initiating hormone therapy in women generally younger than 60 or within about 10 years of menopause onset is where the benefit-to-risk balance is most often favorable [1]. Being years into menopause does not automatically close the door, but it does make an individualized provider review more important, not less.
For early or surgical menopause, guidance is even more pointed. The Menopause Society and endocrine guidance note that women with premature or early menopause have distinct long-term considerations, including bone and cardiovascular health, and are often candidates for hormone support at least until the typical age of natural menopause, absent specific contraindications [1][3]. Continuity, not a one-time handoff, is the point.
How a provider frames each delivery format
A clinician is usually weighing three practical axes: absorption and steadiness of levels, how monitoring works, and how the format fits your life.
Transdermal creams and gels
Estrogen delivered through the skin avoids first-pass liver metabolism, which is the basis for its association with lower clot risk compared with oral routes [1][2]. Creams and gels allow flexible, provider-directed adjustment. The trade-offs a provider will discuss include day-to-day absorption variability, the need to let application sites dry to avoid transferring product to others (a real, documented caution with topical estrogen and testosterone products), and consistency of daily use [2][4].
Injectable formats
Injectable hormones (for example, injectable estradiol esters or, where relevant, testosterone for women under specialist care) bypass the skin and gut entirely. Providers value predictable delivery, but the trade-off is that levels can rise and then fall between administrations, which is why monitoring bloodwork and symptom patterns over time matters. It is worth being precise here: testosterone therapy in women is used off-label and is not FDA-approved for women in the United States; a global consensus position supports its consideration only for specific indications and only with proper monitoring under a knowledgeable clinician [5].
Pellets
Pellets are small implants placed under the skin that release hormone over a period of weeks to months. The convenience is obvious: nothing to apply daily. The clinical caution providers raise is control. Once a pellet is placed, the dose cannot be dialed back if levels run high, and compounded pellet products in particular have drawn specific safety attention. The FDA and The Menopause Society have both cautioned that compounded hormone pellets can produce supraphysiologic (higher-than-natural) hormone levels and that these products are not FDA-approved [4][6].
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Source: [1] The 2022 Hormone Therapy Position Statement of The North American Menopause Society, [4] FDA: Compounding and the FDA - Questions and Answers
Source: [1] The 2022 Hormone Therapy Position Statement of The North American Menopause Society
What monitoring actually looks like
Regardless of format, responsible hormone support is a monitored process, not a set-and-forget prescription. A provider typically reviews baseline health history and may order labs before and periodically during therapy, then adjusts based on how you feel and what your bloodwork shows. Endocrine Society and Menopause Society guidance emphasize periodic reassessment of the benefit-risk balance and shared decision-making rather than a fixed timeline [1][3]. For anyone considering testosterone, monitoring blood levels is specifically emphasized to avoid excess exposure [5].
The reason format connects to monitoring is straightforward: a daily cream can be adjusted quickly, an injection is adjusted over cycles, and a pellet cannot be adjusted at all until it wears off. A provider factors that reversibility into the conversation based on your risk profile and how your body has responded before.
Bringing it back to your situation
If you are running a demanding job and grinding through broken sleep and fog, the format conversation is really a conversation about fit and safety: which route keeps levels steady enough, allows the monitoring your history calls for, and realistically fits your week. If you entered menopause early through surgery, the emphasis shifts toward long-term continuity and a provider who treats early menopause as its own clinical category with its own follow-up, rather than an afterthought to a procedure [1][3].
A prescription is never guaranteed. Whether any hormone support is appropriate, and in which format, is a medical decision made by an independent, licensed provider after reviewing your individual history and labs.
Source: [4] FDA: Compounding and the FDA - Questions and Answers, [5] Global Consensus Position Statement on the Use of Testosterone Therapy for Women
Where Velri fits
Velri is a technology and coordination company, not a medical provider. Velri does not practice medicine and does not guarantee any treatment. What Velri coordinates is the logistics around getting current, balanced care: helping arrange appropriate lab work, connecting you with an independent, physician-led Provider Group licensed in your state, and, if an independent provider determines it is appropriate and writes a prescription, coordinating fulfillment through an independent, licensed pharmacy. Coverage starts in Nevada, with more states rolling out over time.
The goal is simple: remove the friction between you and a provider who works from the current science, so the decision about whether and how to support your vitality is made carefully, with real monitoring, by a licensed clinician who follows through. This article is educational and is not a substitute for personalized medical advice.
